Lexaria Bioscience -CW25LEXXWPreferred / convertible
13F holders, Q4 2024 (December 31)3holders
0new positions
0sold out
$0.85avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding Lexaria Bioscience -CW25 (LEXXW) in their 13F filings, unchanged from Q3 2024. 0 opened new positions and 0 sold out. The largest holders were Heights Capital Management, Inc. ($35K), UBS Group AG ($4K) and Clear Street LLC ($76).
- Company
- Lexaria Bioscience -CW25
- CUSIP
- 52886N117
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 22,986 shares sold, net −22,986 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Heights Capital Management, Inc. | — | No change | 41,251 | $35K |
| UBS Group AG | — | Reduce -81.5% | 5,179 | $4K |
| Clear Street LLC | — | Reduce -50.0% | 100 | $76 |
"% of holder's portfolio" is LEXXW's weight in each manager's 13F, not the share of Lexaria Bioscience -CW25 the manager owns.